ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022
SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial...
Month: October 2022
WW Schedules Third Quarter 2022 Earnings Conference Call
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or “the Company”) will release...
Eargo Announces Record Date for Proposed Rights Offering
Record Date established as October 24, 2022To be a stockholder of record, investors are advised to own EAR stock by...
Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform
WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect...
BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
- Robust post-dosing changes continue to be seen in key markers associated with severity of disease - Pharmacodynamic data from...
Sanofi: Information concerning the total number of voting rights and shares – September 2022
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code...
PathSpot Unveils Handwashing Data From Millions Of Scans In Honor Of Global Handwashing Day
PathSpot scans prove 75% of people do not wash their hands enough; touching money and fake nails contribute the most...
Vystar’s Subsidiary, Rotmans going out of business as Steve Rotman retires from Rotmans Furniture
New England’s largest furniture and flooring store begins liquidation October 14 WORCESTER, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Vystar®...
PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress
BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers...
CORRECTION — SOLVE FSHD invests US$10 Million in Vita Therapeutics
VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- In a release issued today by SOLVE FSHD under the same headline,...
Ramsay Sante : Annual results at the end of June 2022
PRESS RELEASE Paris, October 13th, 2022 Annual results at end June 2022 The solid performance of the Nordic countries has...
Wounded Warriors Family Support, Assurant Present Georgia Marine Veteran with Modified 2022 Chevrolet Silverado 2500 Truck
Wounded Warriors Family Support, Assurant Truck Presentation Assurant, through the Assurant Foundation, teamed with Wounded Warrior Family Support Tuesday to...
SOLVE FSHD invests US$10 Million in Vita Therapeutics
VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- SOLVE FSHD, a venture-philanthropic organization catalyzing the pace of innovation to...
F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim in Invasive Fungal Infections at IDWeek 2022
MANCHESTER, United Kingdom, Oct. 13, 2022 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and...
Merit Medical Systems to Announce Third Quarter Results on October 26, 2022
SOUTH JORDAN, Utah, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and...
IntelGenx’s Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug Candidate
SAINT LAURENT, Quebec, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today provided an update...
Cassava Sciences Announces Initiation of an Open-label Extension Study
Alzheimer’s Patients Who Complete Participation in a Phase 3 Study of Simufilam are Eligible to Enroll52-week Study of Simufilam 100...
T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease
Plans to Initiate Marketing and Sales in the U.S. as a Laboratory Developed Test in 2023LEXINGTON, Mass., Oct. 13, 2022...
Altamira Therapeutics to Participate at RNA Leaders USA Congress
HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Event will be held on October 18-19, 2022 in Boston, MASamuel...